----
Current ValuationThe current P/E ratio is -2.71, within the reasonable range, cheaper than 64.37% of the time in the past 1 years, and the industry ranks 144/257, the industry Median -1.10.
-2.71xP/E
$2.16Stock price
$-0.80Earnings per share
-2.71xP/E
Stock price$2.16Earnings per share$-0.80
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.14x
- Typical range
- -3.14x–-1.67x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03774111148
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAYRYUSBayer | -28.11x | -- | $56.63B |
BAYZFUSBayer Aktiengesellschaft | -28.58x | -- | $57.57B |
VTRSUSViatris | -52.91x | 107.68% | $21.73B |
ELANUSElanco Animal Health | -61.69x | 130.52% | $12.28B |
CURLFUSCuraleaf Holdings, Inc. | -149.19x | -- | $7.76B |
ABVXUSAbivax SA | -16.63x | 22.99% | $7.73B |
AXSMUSAxsome Therap | -46.49x | 31.04% | $7.31B |
VREOFUSVIREO GROWTH INC | -105.44x | -- | $7.08B |
BLTEUSBelite Bio | -59.87x | 29.87% | $6.13B |
MANEUSVeraDermics | -53.53x | 97.44% | $5.58B |
DFTXUSDefinium Therapeutics | -12.69x | 54.55% | $4.49B |
EWTXUSEdgewise Therapeutics | -20.75x | 187.50% | $4.09B |
AMLXUSAmylyx Pharmaceuticals | -24.10x | 1.76% | $3.66B |
ELVNUSEnliven Therapeutics | -31.01x | 5.59% | $3.28B |
TARSUSTarsus Pharmaceuticals | -68.59x | 345.28% | $3.19B |
RGCUSRegencell Bioscience | -260.40x | -- | $3.05B |
BHCUSBausch Health | -3.62x | 511.90% | $3.04B |
MBXUSMBX Biosciences | -25.40x | 31.12% | $2.65B |
PHVSUSPharvaris BV | -12.32x | 10.43% | $2.44B |
TRLVUSTrulieve Cannabis | -4.70x | 198.82% | $2.22B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
